Insulin Degludec for the Management of Patient With Recurrent Diabetic Ketoacidosis
Status:
Terminated
Trial end date:
2020-09-25
Target enrollment:
Participant gender:
Summary
Given the longer half life of insulin degludec compared to glargine /levemir ,investigators
believe that insulin degludec will reduce the rate of recurrent DKA. The investigator will
randomize participants to control and intervention group. Control group will receive
Lantus/Levemir and intervention group will receive degludec. The investigators will call
participants monthly and see them in the clinic every three months.The investigators will
follow them for 1 year and evaluate if there will be a difference in rate of DKA in between
these two groups.
Phase:
N/A
Details
Lead Sponsor:
Hennepin Healthcare Research Institute Minneapolis Medical Research Foundation